



Competitive Intelligence & Technology Monitoring-Targeted Protein Degradation

Case Study

Case Study 1: Competitive Intelligence & Technology Monitoring- Targeted Protein Degradation (1/2)

Present Landscape, Target and Entity Screenings and Continuous monitoring

Client	Global Integrated Biopharma
Industry	Bio-pharmaceuticals
Products	Targeted Protein Degradation

Background

- The Client is a leading research based bio-pharmaceutical company with its presence across different geographies into various therapy areas. Their existing portfolio exists largely around innovative drugs and have interest to continuously monitor key developments across next wave of treatment modalities

Context

- The Client was interested in identification and selection of novel treatment modalities/solutions which can overcome the unmet needs of present solutions. In one of the last studies, FB recommended Targeted Proteolysis technology as one of the solutions. Therefore the Client was interested to screen and achieve comprehensive assessments of Targeted Proteolysis technology through patent and scientific literature published, early scientific sentiments, key update on the clinical developments in this domain, assess competitors' activities corresponding to this technology and a continuous monitoring scheme of the key activities in this domain.

Engagement Scope

1

Study Scope

- What is the overall landscape of targeted protein degradation platforms/modalities with a focus on Oncology?
- What are the unmet needs that would be addressed by these technologies ?
- What is the entity ecosystem **utilizing specific platform** for developing new modalities?
- How the competitors are positioning themselves with respect to programs and scientific evidences corresponding to specific technology?
- What are the various **programs/candidates** in development using this platform?
- What is the **patent portfolio** of the identified platforms?

2

Approach

- Exhaustive Secondary Research – PubMed, Scientific Journals, Industry Reports & Articles, Company websites & publications, Regulatory and Reimbursement websites, Clinical trial registries
- Primary Research – Focused group discussions, detailed interviews and web survey with – Biotech & Chemical Technology experts, Oncologists, other medical practitioners, manufacturers, industry participants, regulatory consultants, reimbursement experts, patient educators

3

Results & Insights

- In depth technology understanding provided opportunities for additional collaboration needs across stakeholders and partners ecosystem
- Prioritizing strategic development programs within R&D portfolio with Novel Modalities
- Continuous update to the core team with on-going developments provided time window implement actions/decisions
- Knowledge landscape formed the base for the development team to understand the key therapy areas that are being developed through these routes

Thank you

North America

55 Madison Ave, Suite 400
Morristown, NJ 07960
USA
T: +1 212 835 1590

Europe

328-334 Graadt van Roggenweg
4th Floor, Utrecht, 3531 AH
Netherlands
T: +31 30 298 2108

United Kingdom

5 Chancery Lane
London EC4A 1BL
United Kingdom
T: +44 207 406 7548

Asia Pacific

Millennium Business Park
Sector 3, Building # 4, Mahape
Navi Mumbai 400 710
India
T: +91 22 6772 5700